Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2005; 26(04): 43-57
DOI: 10.1055/s-0041-1733134
Review Article

Hepatocellular Carcinoma

PM Parikh
Department of Medical Oncology,Tata Memorial Hospital, Mumbai, India
,
R Bhagwat
Department of Medical Oncology,Tata Memorial Hospital, Mumbai, India
,
G Biswas
Department of Medical Oncology,Tata Memorial Hospital, Mumbai, India
,
L Goyal
Department of Medical Oncology,Tata Memorial Hospital, Mumbai, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
28 March 2022

© 2005. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Bosch FX, Ribes.J, Borras J. Epidemiology of primary liver cancer: Semin Liver Dis 1999;19:271-285.
  • 2 El-Serag HE, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
  • 3 Montalto G, Cervello M, Giannitrapani L, et al.: Epidemiology, risk factors and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002;963:13-20.
  • 4 Hassan MM, Frome A, Patt YZ, et al.: Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcilloma in the United States. J Clin Gastroenterol 2002;35:266-269.
  • 5 Mor E, Kaspa RT, Sheiner P. et al: Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med 1998;129(8):643-53.
  • 6 Blunlberg BS, Laroze B, London WT, et al. The relation of infection with the hepatitis B agent to primary hepatic carcinoma. Am J Pathol 1975;81(3):669-82.
  • 7 Tsukanla 8; Hiyama T, Tanaka S, et al.: Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328(25):1797- 801.
  • 8 Yang HI, Lu SN, Liaw YF, et al.: Hepatitis Be antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-174.
  • 9 Tagger A, Donaro F, Ribero ML, et al.: Case control study on Hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism between hepatitis B virus and alcohol. Brescia HCC Study Int J Cancer 1999;81(5):695-9.
  • 10 Yu MW, Chang HC, Liaw YF. et al.: Familial risk of hepatocellular carcinoma chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92(14):1159- 64.
  • 11 Thyagarajan SP. Prevalence of Hepatitis B virus infection in general population of Indian. Ind. Jn. Gastroentero 2000;19(SuppI3).
  • 12 Singh J, Prakash C, Gupta RS, et al. Epidemiology of endemic viral hepatitis in an urban area of India: a retrospective study in Alwar: Bulletin WHO 1997;75:463-8.
  • 13 Mohandas KM. Epidemiology of HBV-associated Hepatocellular Carcinoma in India. Ind. Jn. Gastroenter 2000;19(Suppl 3);74-78.
  • 14 Chaudhuri S, Das S, Chowdhury A, et al. Molecular epidemiology of HCV infection among acute and chronic liver disease patients in Kolkata, India. J Clin Virol 2005;32(1):38-46.
  • 15 Singh S, Malhotra V, Sarin SK.Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res 2004;119(4):145-8.
  • 16 Vivekananda P. Abraham P. Sridharan G, et al. Distribution of hepatitis B genotypes in blood donors and chronically infected patients in a tertiary care hospital in southern India. Clin Infect Dis 2004;38(9):e81-6.
  • 17 Thakur V, GUPtn RC, Hasmhi AZ, et al. Absence of hemochromatosis associated Cys282 Tyr HFE gene mutation and low frequency of haemochromatosis phenotype in non alcoholic chronic liver disease patients in India. J Gastroenterol Hepatol. 2004;19(1):86-90.
  • 18 Xess A, Kumar M. Prevalence of hepatitis B & hepatitis C virus coinfection in chronic liver disease. Ind. J Pathol Microbiol 2001;44(3):253-5.
  • 19 Singh B, Verma M, Verma K. Markers for transfusionassociated hepatitis in north Indian blood donors: prevalence and trends. Jap. Jn. Inf. Dis. 2004;57(2):49-51.
  • 20 Sherman H, Hardison J. The importance of coexistent rubs and bruit. JAMA 1979;241:1495-1498.
  • 21 Yeo W, Surg JY, Ward SC, et al.: A prospective study of upper gastrointestinal hemorrhage in patients with hepatocellular carcinoma. Dig Dis Sci 1995;40.:2516-2521.
  • 22 Lin TY. Tumours of liver: I. Primary malignant tumours. IN: Bockus HS; Ed, Gastroenterology,3rd ed. Philadelphia: WB Saunders, 1976:522.
  • 23 Lau WY, Leung KL, Leung TW, et al.: Obstructive jaundice secondary to hepatocellular carcinoma. Surg Oncol 1995;4:303-308.
  • 24 Kew MC, Dusheiko GM. Paraneoplastic manifestations of hepatocellular carcinoma. In: Berk PD, Chalmers TC, Eds. Frontiers of liver and disease. New York: Thieme Stratton, 1981:305.
  • 25 Lau JWY, Leow CK. Surgical management (including liver transplantation). In: Leong ASY Liew CT, Lau JWY, Johnson PJ, eds: Hepatocellular carcinoma. Diagnosis, investigation and nlanagement. London: Arnold, 1999:147.
  • 26 Fong Y, Sun RL, Jarnagin W, et al: All analysis of 412 cases of hepatocellular carcinoma at a western centel: Ann Surg 1999;229(6):790-9.
  • 27 Tsuzuki T, Sugoika A, Ueda M, et al: Hepatic resection for hepatocellular carcinonla. Surgery 1990;107:511-520.
  • 28 Vauthey JN, Klimstra D, Franceschi D, et al: Hepatic resection for hepatocellular carcinoma. Am J surg 1995;169:28-34.
  • 29 Sitzmann JV, Abrams R. Improved survival for hepatocellular carcinoma with combination surgery and multimodality treatment. Ann Surg 1993;217:149-154.
  • 30 Lau Wy, Leung KL, Leung TW, et al: Resection of hepatocellular carcinoma with diaphragmatic invasion. Brit J. cancel: 1995;82:264-266.
  • 31 Yamanaka N, Okamoto E, Fujihara S, et al: Do the tumour cells of hepatocellular carcinomas dislodge into the portal venous system during hepatic resection? Cancer 1992;70:2263.
  • 32 Selby R, Kedry Z, Carr B et al: liver transplantation for hepatocellular carcinoma. World J Surg 1995;19:53.
  • 33 Blunlgart LH. Liver resections- Liver and biliary tumours. In Blumgart LH, ed. Surgery of the liver and biliary tract. New York: Churchill Livingstone, 1998:1251.
  • 34 O' Grady JG, Polson RJ, Rolles K, Calne RY, Williams R. Liver transplant for malignant disease. Ann Surg 1988;207:373.
  • 35 Swartz Me, Sung M, Mor E,et al. A multidisciplinary approach to hepatocellular carcilloma in patients of cirrhosis. J Am Coll Surg 1995;180:596.
  • 36 Mazzafero V, Regalia E, Doci R, et al. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693.
  • 37 Figueras J, Jaurrieta E, Valls C, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes base on indicated treatment state. J Am Coll Surg 2000;190(5):580-7.
  • 38 Makuuchi M. Surgical treatment for hepatocellular carcinoma in: Arroyo V, Bosch J, Bodes J, eds. Treatment in hepatology. Barcelona Masson. 1995;341- 352.
  • 39 Nagasue N, Kohno H, Chang YC, et.al. Liver resection of hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993;217:375-384.
  • 40 Tang ZY, YU, YQ, Zhou XD. Evolution of surgery in the treatment of hepatocellular ca. from 1950s to 1990s. Semiin Surg OncoI 1993;9:293-297.
  • 40 Balsells J, Charco R, Lazaro JL, Murio E, Vargas V, Allende E, Margarit C. Resection of hepatocellular carcinoma in patients with cirrhosis. Br J Surg 1996:83:758-761.
  • 40 Llovet J, Fuster J, Bruix J. Intention-to-Treat analysis of early surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-40.
  • 40 Shabahang M, Franceschi D, Yamshiki N, et al. Colnparison of hepatic resection and hepatic transplantation ill the treatment of hepatocellular carcinoma anlong cirrhotic patients. Ann. Surg. Oncol.2002;9(9):881-886.
  • 40 Simonetti RG, Liberati A, Angilini C, et al. Treatment of hepatocellular carcinoma: a systemic review of RCT Ann OncoI 1997;8:117.
  • 40 Mathurin P, Rixe 0, Carbonell L, et al. Review article: Overview of medical treatments in hepatocellular carcinoma- an impossible meta-analysis. Aliment Pharmaco Tllera 1998;12:111.
  • 40 Takayama T, Sekine T, Makucuchi M, et al.: Adoptive immunity to lower post surgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000;356(9232):802-7.
  • 40 Higuchi T, Kikuchi M, Okazaki M, Hepatocellular carcinoma after transcatheter hepatic arterial embolization: a histopathologic study of 84 resected cases. Cancer 1994;73:2259-67.
  • 40 Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization inproves survival. Hepatology 2003;37:429,42.
  • 40 Huang YH, Wu JC, Chau GY, et al. Supportive treatment, resection and transcatheter arterial cehmoembolization in respectable hepatocellular carcinoma: an analysis of survival in 419 patients. Eur J Gastroenterol Hepatol 1999;11:315-21.
  • 50 Lau WY, Leung TW Yu SC, et al. Percutaneus local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 2003;.237:171-9.
  • 51 Gaiani S. Celli N, Cecilioni L, et al. Percutaneus treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2003;17(SuppI 2):103-10.
  • 52 Lencioni R, into F, Armillotta N, et al. Long term results of percutaneus ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur RadioI1 997;7:514-19.
  • 53 Castells A, Bruix J, Bru C et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneus ethanol injection. Hepatology 1993;18:1121.6.
  • 54 Shuto T, Hirohashi K, lkebe T, et al. Additional hepatocellular carchionma undetectable before surgery. World J Surg 2000;24:1566-9.
  • 55 Yamamoto J, Okada S, Shimada K, et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneus ethanol injection therapy and surgical resection. Hepatlogy 2001;34:707-13.
  • 56 Huo TI, Huang YH, Wu JC, et al. Survival benefit of cirrhotic patients with hepatocellular carcinoma treated by Percutaneous ethanol injection therapy as a salvage therapy. Scand J GastroenteroI 2002;37:350- 5.
  • 57 Livraghi T, Benedini V, Lazzaroni S, et al. Long term results of single session percuateneus ethanol injection in patients with large hepatocellular carcinoma. Cancer 1998;83:18-57.
  • 58 Ohnishi K, Ohyama N, Ito S, et al. Ultrasound guided intratumour injection of acetic acid for the treatment of small hepatocellular carcinoma. Radiology 1994;193:747-52.
  • 59 Ohnishi K, Nomura 1F, Ito S et al. Prognosis of small Hepatocellular carcinoma (less than 3 cms) after percutaneous acetic acid injection: study of 91 cases. Hepatology 1996;23:994-1002.
  • 60 Ohnishi K, Yoshioka H, lto S, et al. Prospective randomized controlled trial comparing of percutaneus acetic acid and percutaneus ethanol injection for small hepatocellular carcinoma. Hepatology 1998;27:67-72.
  • 61 Huo T, Huang YH, Wu JC, et al. Comparison of percutaneus acetic acid and percutaneus ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study Scand J Gastroentero] 2003;38:770-8 .
  • 62 Rossi S, Fornari F, Buscarini. Percutaneus ultrasound guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma. J lnterv Radio 1993;8:97-103.
  • 63 Lencioni RA, Allgaier Hp, Cioni D, et al. Small hepacellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneus ethanol injection. Radiology 2003;228:235-40.
  • 64 Poon RT, Ng KK, Lam CM, et al. Effectiveness of radiofrequency ablation for HCC larger than 3 cm in diameter. Arch Surg 2004;139:281-7.
  • 65 Vivarelli M, Guglielmi A, Ruzzenente, et al. Surgical resection versus percutaneus radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver Ann Surg 2004;240:102-7.
  • 66 Mulier S, Mulier P, Ni Y, et al. Complications of radiohequency coagulation of liver tumours. BR J Surg 2002;89:1206-22.
  • 67 Llovet JM, Vilana R, Bru, et al. lncreased risk of tumour seeding after Percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124-9.
  • 68 Hamazoe R, Hirooka Y, Ohtani S, et al. Intraoperative microwave tissue coagulation as treatment for patients with nonresectable hepatocellular carcinoma. Cancer 1995;75:794-800.
  • 69 Abe T, Shinzawa H, Wakabayashi H, et al. Value of laproscopic microwave coagulation for hepatocellular carcinoma in relation to tumour size and location. Endoscopy 2000;32:598-603.
  • 70 Matsukawa T, Yamashita Y, Arakawa A, et al. Percuataneus microwave coagulation therapy in liver tumours. A 3 year experience. Acta Radiol 1997;38:410- 15.
  • 71 Itamoto T, Katayama K, Fukuda S et al. Percutaneous microwave coagulation therapy for primary or recurrent hepatocellular carcinoma: Long term results. Hepatogastroenterology 2001;48:1401-5.
  • 72 Seko M, Wakabayashi M, Nakagawa T, et al. Percutaneus microwave coagulation therapy for patients with small hepatocellular carcinoma: comparison with percutaneus ethanol injection therapy. Cancer 1999;85:1694-702.
  • 73 Sato M, Tokui K, Watanabe Y, et al. Generalised intraperitoneal seeding of hepatocellular carcinoma after percutaneus microwave coagulation therapy: a case report. Hepatogastoenterology 1999;46:2561-4.
  • 74 Koda M, Murawaki Y, Mitsuda A, et al. Combination therapy with transcatheter arterial chemotherapy and percutaneus ethanol injection compared with percutaneus ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 2001;92:1516-24.
  • 75 Seki T, Tamai T, Nakagawa T, et al. Combination therapy with transcatheter arterial chemotherapy and percuataneus microwave coagulation therapy for hepatocellula.r carcinoma. Cancer 2000;89:1245-51.
  • 76 Huo TI, Huang YH, Wu JC, et al. Sequential transarterial chemoembolization and percutaneus acetic acid injection therapy versus repeated percutaneus acetic acid injection therapy for unresectable Huo TI, Huang YH, Wu JC, et al.: a prospective study: Ann Oncol 2003;14:1648-53.
  • 77 Rossi S, Oarbangnati F, Lencioni R, et al. Percutaneus radiofrequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumour blood supply: Radiology 2000;217:119-26.
  • 78 Huo TI, Huang YH, Wu JC, et al. Induction of complete tumour necrosis may reduce intrahepatic metastasis and prolong survival in patients with hepatocellular carcinoma undergoing locoregional therapy: a prospective study: Ann Oncol 2004;15:775-80.
  • 79 Huo T, Lee S. Management of inoperable hepatocellular carcinoma. Jn. Gastro. and Hepato1 2004;19:S272-S278.
  • 80 Lawrence TS, Dworzanin LM, Walker- Andrews TS, et al. Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys 1991;20:555;
  • 81 Robertson JM, Lawrence TS, Andrews JC, et al. Longterm results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. Int J Radiat Oncol Biol Phys 1997;37(2):325-330.
  • 82 Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676- 1681.
  • 83 Kiss A, Wang NJ, Xie JP, et al. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth factor/cmet, TGF-beta receptor type II and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997;3:1059.66.
  • 84 Wang L, Abou-Alfa OK, Lui F, et al. Methodology of response assessment in hepatocellular carcinoma (HCC) -Assessing response by change in tumour enhancement in distinction to conventional means. Proc Am Soc Clin Oncol 2004;abst:3107.
  • 85 Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependant kinases (CDK) 2 and CDK$ in human breast cancer cells. Cancer Res 1996;56:2973-78.
  • 86 Schwartz JD, Lehrer D, Mandeli J, et al. Thalidomide in hepatocellular cancer (HCC) with optional interferon- alfa upon progression. Proc Am Soc Clin Oncol 2003;33:301(abstr 1210).
  • 87 Schwartz JD, Schwartz M, Kinkhabwala M, et al. Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein. Gast Can Sym p1: 2004;(abstr 128)
  • 88 Aruga A, Yamauchi K, Takasaki K, Furukawa T, Hanyu F, Induction of autologus tumour specific cytotoxic T cells in patients with liver cancer: characterizations and clinical utilization. Int J Cancer 1991;49:19-24.
  • 89 Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000;356:802-7.
  • 90 Nagusue N, Yu L, Yukaya H, Kohno H, Nakamura T, Androgen and estrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br J Surg 1995;82(4):542.
  • 91 Berman E, Adams M, Duigou-Osterndorf R, et al. Effect of Tamoxifen on cell lines displaying the multidrug resistant phenotype. Blood 1991;77(4):818-825.
  • 92 Farinati F, De Maria N, Fornasiero A, et al. Prospective controlled trial with anti-estrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Sci 1992;37:659-662.
  • 93 Forbes A, Wilkinson ML, Iqbal MJ, et al. response to cyproterone acetate treatment in primary hepatocellulaar carcinoma is related to fall in free 5adihydrotestosterone. J Cancer Res Clin Oncol 1987;23:1659-1664.
  • 94 Nakajima Y, Ko S, Kanamura T, et al. Repeat liver resection for hepatocellular carcinoma. J Am ColI Surg 2001;192(3):339-44.
  • 95 Neeleman N, Anderson R: Repeated liver resection for recurrent liver cancer: Br J Surg 1996;83(7):893-901.
  • 96 Poon RT, Fan ST, Lo CM, et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long term results of treatment and prognostic factors. Ann Surg 1999;229(2):216.22.
  • 97 Lok AS. Prevention of hepatitis b virus-related hepatocellular carcinoma. Gastroenterology 2004;127:(5Suppl 2):s303-9.
  • 98 Dasgupta R, Priya R. The sustainability of hepatitis B immunization within the Universal Immunization Programme in India. Health and Planning 2002;17(1):99- 105.
  • 99 Dhotilal A, Kapoor D, Kumar N. Seroprevalence of hepatitis A virus antibody in patients with chronic liver disease- experience from a tertiary care hospital in north India. Trop Gastroenterology 2002;23(4):170-1.
  • 100 Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004;127(5 Supp1 2):s294-302.
  • 101 Prorok PC: Epidemiologic approach for cancer screening. Problems in design and analysis of trials. Am J Pediatr Hematol Oncol 1992;14:117-128.
  • 102 Bolondi L, Sofia S, Siringo S, et al: Surveillance program of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001,48:149.150.103. Collier J, Sherman M: Screening for hepatocellular carcinoma. Hepatology 1998;27:273-278.
  • 103 Bruix J, Sherman M, Llovet JM, et al. : Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatology 2001;35:421-430.
  • 104 Trevisani F, De NS, Rapaccini G, et al. : Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-744.
  • 105 Tarao K, Fujiyama S, Ohkawa S, et al. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus associated liver cirrhosis. Cancer Epidemiol Biomarkers Prev. 2005;14(1):164-69.
  • 106 Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumours by an acycliv retinoid, polypenoic acid in patients with hepatocellular carcinoma. Hepatoma prevention Study Group. N Engl J Med 1996;334:1561-7.
  • 107 Otsuka M, Kato N, Shao Rx, et al. Vitamin K2 inhibits growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004;40:243-51.